Choon Hee Chung Selected Research

lobeglitazone

11/2022	A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus.
10/2017	Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks.
12/2015	Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study.
1/2014	Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Choon Hee Chung Research Topics

Disease

37	Type 2 Diabetes Mellitus (MODY) 11/2022 - 07/2006
23	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 02/2004
20	Insulin Resistance 01/2019 - 02/2007
14	Inflammation (Inflammations) 01/2022 - 06/2005
13	Albuminuria 01/2021 - 10/2007
8	Obesity 01/2021 - 09/2013
7	Body Weight (Weight, Body) 01/2022 - 01/2006
6	Neoplasms (Cancer) 10/2021 - 06/2005
5	Fibrosis (Cirrhosis) 01/2022 - 01/2015
5	Non-alcoholic Fatty Liver Disease 01/2020 - 01/2009
5	Hypertension (High Blood Pressure) 09/2017 - 10/2011
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2015 - 01/2009
4	Proteinuria 01/2015 - 02/2004
3	Weight Gain 11/2022 - 01/2014
3	Kidney Diseases (Kidney Disease) 01/2019 - 11/2012
3	Hypoglycemia (Reactive Hypoglycemia) 05/2016 - 02/2004
3	Cardiovascular Diseases (Cardiovascular Disease) 05/2015 - 06/2011
2	Peripheral Nervous System Diseases (PNS Diseases) 11/2022 - 01/2022
2	Wounds and Injuries (Trauma) 01/2022 - 01/2021
2	Diabetes Mellitus 12/2020 - 02/2012
2	Dyslipidemias (Dyslipidemia) 10/2020 - 09/2013
2	Glucose Intolerance 01/2018 - 01/2015
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2017 - 01/2015
2	Sarcopenia 07/2015 - 01/2015
2	Hyperinsulinism (Hyperinsulinemia) 09/2013 - 02/2004
1	Urinary Bladder Neoplasms (Bladder Cancer) 11/2022
1	Heart Failure 11/2022
1	Pain (Aches) 11/2022
1	Neuralgia (Stump Neuralgia) 01/2022
1	Postherpetic Neuralgia 01/2022
1	Hyperaldosteronism (Conn Syndrome) 10/2021
1	Adenoma (Adenomas) 10/2021
1	Cushing Syndrome 10/2021
1	Fabry Disease (Fabry's Disease) 01/2021
1	Hypertrophy 01/2021
1	Lysosomal Storage Diseases (Lysosomal Storage Disease) 01/2021
1	Skin Diseases (Skin Disease) 01/2021

Drug/Important Bio-Agent (IBA)

17	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2006
11	Insulin (Novolin)FDA Link 01/2020 - 02/2004
9	LipidsIBA 10/2020 - 01/2006
8	CreatinineIBA 01/2021 - 02/2009
8	AlbuminsIBA 01/2021 - 02/2009
7	Metformin (Glucophage)FDA LinkGeneric 10/2018 - 02/2007
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014 - 02/2004
6	Triglycerides (Triacylglycerol)IBA 10/2020 - 02/2006
5	CurcuminIBA 01/2022 - 05/2016
5	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2006
5	AntioxidantsIBA 01/2019 - 06/2011
4	lobeglitazoneIBA 11/2022 - 01/2014
4	Proteins (Proteins, Gene)FDA Link 12/2020 - 01/2009
4	AdiponectinIBA 01/2017 - 01/2009
3	ThiazolidinedionesIBA 11/2022 - 04/2007
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2022 - 02/2012
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 01/2006
3	CytokinesIBA 01/2021 - 06/2005
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2021 - 07/2009
3	Therapeutic UsesIBA 01/2019 - 12/2011
3	Sitagliptin Phosphate (Januvia)FDA Link 10/2018 - 01/2017
3	CC ChemokinesIBA 01/2017 - 07/2013
3	ORALIT (ORS)IBA 01/2017 - 10/2011
3	Angiotensin Receptor AntagonistsIBA 10/2016 - 02/2004
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2014 - 10/2012
3	C-Reactive ProteinIBA 10/2011 - 01/2009
2	EnzymesIBA 01/2021 - 05/2009
2	NADP (NADPH)IBA 01/2021 - 02/2009
2	NADPH Oxidases (NAD(P)H oxidase)IBA 12/2020 - 02/2009
2	HDL CholesterolIBA 10/2020 - 01/2009
2	Angiotensin IIIBA 01/2019 - 02/2004
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 11/2012
2	Biomarkers (Surrogate Marker)IBA 03/2018 - 01/2014
2	LC15-0444IBA 01/2018 - 01/2017
2	4- (3- amino- 4- (2,4,5- trifluorophenyl)butanoyl)- 3- (tert- butoxymethyl)piperazin- 2- oneIBA 12/2017 - 01/2017
2	2,4-thiazolidinedione (thiazolidinedione)IBA 10/2017 - 04/2007
2	Pioglitazone (Actos)FDA Link 04/2017 - 12/2008
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2016 - 01/2015
2	Uric Acid (Urate)IBA 07/2015 - 09/2013
2	SodiumIBA 07/2015 - 01/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 02/2007
2	nephrinIBA 07/2013 - 11/2012
2	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 03/2013 - 05/2009
2	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 05/2009 - 01/2009
2	Rosiglitazone (Avandia)FDA Link 12/2008 - 02/2007
2	AdipokinesIBA 09/2007 - 02/2007
1	NAD (NADH)IBA 11/2022
1	insulin glulisine FDA Link 01/2022
1	Short-Acting InsulinIBA 01/2022
1	Pregabalin (Lyrica)FDA Link 01/2022
1	vactosertibIBA 01/2022
1	Hormones (Hormone)IBA 10/2021
1	SteroidsIBA 10/2021
1	N 30IBA 10/2021
1	Dronabinol (THC)FDA LinkGeneric 01/2021
1	alpha-Galactosidase (Beano)IBA 01/2021
1	globotriaosyl lysosphingolipidIBA 01/2021
1	Glycerol (Glycerine)FDA LinkGeneric 01/2021
1	Oxidoreductases (Dehydrogenase)IBA 01/2021
1	Beclin-1IBA 01/2021

Therapy/Procedure

9	Therapeutics 10/2020 - 02/2014
2	Aftercare (After-Treatment) 01/2018 - 06/2015
2	Glycemic Control 01/2015 - 01/2015